drugset / Trial / NCT03389893
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Phase 4
Terminated
72 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis Research Network · collabRegeneron Pharmaceuticals · collabRho Federal Systems Division, Inc. · collabSanofi · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal lipids.
Timeline
- Start
- 2018-07-25
- Primary completion
- 2020-04-03
- Completion
- 2020-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |